$3.470
-0.135 (-3.88%)收盘时
PRME 资讯
PRME 事件
Prime Medicine Initiates PM577a Clinical Trial
Prime Medicine announced that the first patient has been dosed in the company's global Phase 1/2 clinical trial of PM577a, an investigational in vivo Prime Editor for H1069Q-mutated Wilson disease. The milestone marks the initiation of the first clinical study of an in vivo Prime Editing therapy from Prime Medicine, as well as the first clinical evaluation of the company's liver franchise. The company also announced that the FDA has granted Rare Pediatric Disease designation to PM577 for Wilson disease.
Meta Platforms Stock Rises 4.5% to Year High
Major indices looked to be headed for a second consecutive sizable decline as rising Treasury yields continued to thwart the AI buildout narrative, though sentiment turned less panicked after headlines indicating that U.S and Iran discussing phased deal to reopen Hormuz Strait. WTI Crude Oil - which had bounced above $96 per barrel - retreated to $94. The yield on the 10-year had briefly fallen 4 basis points on the report to 5.13%, but traders faded the rally in Treasuries, and that yield ended the day back around the highs.Communication Services was the best performing sector in the benchmark S&P 500. The sector is powered by the ongoing advance in Meta Platforms, where the 4.5% rise today following the company's VR Glasses and Muse Charm product announcementshas taken the stock to its highest level of the year. Meta is now up 18% year-to-date and up 44% from its mid-August lows. Basic Materials and Utilities were the worst performing sectors on Thursday.In the opening hour of the evening session, index futures are slightly lower, with S&P e-minis and Nasdaq 100 contracts both down 0.2%. In commodities, precious metals remain under modest pressure as US Dollar continues to advance with Gold just above $4,300 and Silver above $64 per ounce.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Costco Wholesaleup 0.2%ALSO HIGHER -Akamai Technologiesup 22.2% after announcing $11.6B multi-year agreement with AnthropicPrime Medicineup 14.3% after FDA clearance of IND application for PM647Select Water Solutionsup 10.9% after announcing acquisition of Pilot Water Solutions for $700MAtlas Energy Solutionsup 8.6% after disclosing $340.5M contractPeople Incorporatedup 8.5% after WSJ report that MGM is considering bid for companySTAAR Surgicalup 4.7% after $50M buybackT-Mobile USup 1.0% after dividend increaseDOWN AFTER EARNINGS -Scholasticdown 11.9%Legacy Educationdown 10.7%Rezolutedown 2.5%ALSO LOWER -Zscalerdown 3.9% after announcing transition of Chief Revenue Officer
Prime Medicine Receives FDA Clearance for PM647 Clinical Study
Prime Medicine announced that the FDA has cleared the company's Investigational New Drug, or IND, application for PM647, an investigational in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency. The clearance enables PM647 to proceed to clinical study initially in the United States, where approximately 100,000 people carry the PiZZ genotype that PM647 is designed to correct.
Prime Medicine Q4 Revenue $1.15M Beats Expectations
Reports Q4 revenue $1.15M, consensus $1.11M. "We have continued to deliver on the focused strategy we laid out last year," said Allan Reine, Chief Executive Officer of Prime Medicine. "Wilson disease is now cleared to enter the clinic in two geographies. Our rights in Alpha-1 Antitrypsin Deficiency are secure, and the program is advancing toward regulatory submission. And in CGD, where Prime Editing has already shown it can correct disease in humans, we are working toward a BLA filing, and delivering this therapy to patients in need. The opportunity ahead of us is to demonstrate that same potential effect in vivo, in two of the largest genetic diseases targeting the liver."
Stocks Broadly Down as Oil Prices Surge
Stocks spent the session broadly in the red as oil prices surged once again after the U.S. launched new strikes on Iran, with President Trump saying the ceasefire is "over." WTI crude oil futures settled at $73.52 per barrel, up over 4%, on fears that renewed hostilities and attacks near the Strait of Hormuz could disrupt global energy supplies. The rally boosted shares of oil producers, while weighing on airlines, cruise operators and other travel-related stocks that are sensitive to higher fuel costs.Meanwhile, the Federal Reserve released the minutes from its last meeting, in which it said a "few" members saw the case for a June rate hike, though those participants indicated that they supported maintaining the current target range at this meeting. Additionally, the Fed said in the minutes that most participants remarked on scenarios in which inflationary pressures would dissipate and inflation would soon begin to return to 2%. In such scenarios, almost all of these participants noted that it would likely be appropriate to maintain or eventually lower the target range for the federal funds rate.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:After U.S. Central Command launched strikes on targets in Iran in response to its attacks on commercial vessels passing through the Strait of Hormuz, U.S. President Donald Trump said that the U.S.Appleannounced awith Broadcomto design and produce custom silicon components and cutting-edge wireless connectivity technologiesDream Finders HomeshasBeazer Homesfor $32 per shareChina will allow top AI companies to buy some NvidiaH200 chips,A "few" Federal Reserve members said they saw the case for a June rate increase, though they also supported maintaining the current target range,2. WALL STREET CALLS:Dollar Treeto Outperform at Raymond James and to Neutral at Goldman SachsOccidentalto Outperform at Evercore ISIBarclaysCommunity Healthto Underweight while also downgrading HCA Healthcareand Universal Healthto Equal WeightBath & Body Worksto Sell at Goldman SachsJPMorganOllie's Bargain Outletto Neutral, sees Q2 miss3. AROUND THE WEB:Hunterbrook published a short report on Bloom Energy, though the company told Bloomberg it plans to "correct the record"OpenAI will publicly launch GPT-5.6, its most advanced AI model, on Thursday following a delay last month prompted by U.S. government requests over heightened national security concerns about the potential misuse of powerful AI technologies, Reuters saysJPMorgan Chaseis planning to target small-company deals, establishing a new team of investment bankers focused on small-cap companies valued between $100M-$500M, WSJ reportsSK Hynix's$28B ADR offering is seeing strong investor demand, with orders oversubscribing the deal ahead of pricing and allocation later in the week, Reuters saysLast week, Tate Bennett, chief of staff for USDA Secretary Brooke Rollins, spoke with grocers including Walmart, Kroger, and Albertsonsasking about their prices for beef heading into the holiday weekend, WSJ reports4. MOVERS:Prime Medicinegained after the company reported awith Beam TherapeuticsPenguin Solutionswas higher afterand increasing its guidance for FY26Redwireincreased after appointing Paul Reichert and Niki WerkheiserFuelCellwas lower after announcing aNavitasfell after Wolfspeedfiled aagainst the company5. EARNINGS/GUIDANCE:Helen of Troyand reaffirmed its guidance for FY27Sono-Tek, with the company commenting, "Fiscal 2027 is off to a strong start"Palladyne AIreportedHyperscale Databacked itsEnerpac Toolsand raised its guidance for FY26INDEXES:The Dow fell 576.76, or 1.09%, to 52,348.39, the Nasdaq gained 51.96, or 0.20%, to 25,870.65, and the S&P 500 declined 21.14, or 0.28%, to 7,482.71.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。